Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.

Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.

Community physicians must be “smart” when it comes to initiating outpatient care with agents like ramantamig for multiple myeloma, according to Jeffrey V. Matous, MD.

William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.

Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.

William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.

William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.

Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.